FeesSafety
Pluang+
Home/Explore/US Market Price/Stocks/REGN
icon
Up to 4x
Us company
Asset icon - trade crypto, stocks, and gold on Pluang

Regeneron Pharmaceuticals Inc (REGN) Stock Price Today

TechnicalsFundamentalsFinancialsNewsCorp ActionAboutCompare
24H
1W
1M
3M
YTD
1Y
5Y

Aura AI Summary

Regeneron Pharmaceuticals (REGN) trades at $954.81, up 4.23% with strong technical momentum and bullish moving averages. The company demonstrates robust fundamentals with $14.34B revenue, 28.51% net margin, and consistent earnings beats. Recent expansion of the Sanofi immunology alliance, including $1B upfront and up to $7B in milestones, provides significant growth catalysts. Technical indicators show the stock trading near resistance at $981 with support at $918.
Regeneron presents a compelling investment case with strong profitability, strategic partnerships, and positive analyst sentiment (69% buy ratings). Key risks include competitive pressures in ophthalmology and reliance on key products. With the current price above the $894.89 consensus target, near-term upside may be limited despite strong fundamentals and recent clinical trial successes.
Read full analysis

Key Stats

  • Market Cap
    $99.25B
  • Volume
    1,220,674
  • Sector
    Health
  • 52W High
    $973.36
  • 52W Low
    $600.66
  • Typical Hold Time
    108 Days
  • Enterprise Value
    $92.65B
  • Div Yield
    0.39%
  • Trading Activity
    0% Sell | 100% Buy
$952.78
52W Low: $600.66
01 Jun 2026
52W High: $973.36
03 Nov 2026

Track Regeneron Pharmaceuticals Inc (REGN) stock price today on Pluang, updated in real time with live charts and market data. Over the past 52 weeks, Regeneron Pharmaceuticals Inc has traded between a low of $600.66 and a high of $973.36, highlighting its annual price range. Buy and sell Regeneron Pharmaceuticals Inc shares on Pluang with fractional shares and real-time market data — safe and OJK-regulated.

About Regeneron Pharmaceuticals Inc

Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases

Most Recent News

Content is generated by Aura AI

Over 100 BCMA-targeted therapies in development are driving innovation in multiple myeloma treatment.

DelveInsight's 2026 report highlights more than 100 BCMA-targeted therapies in various clinical stages, focusing on multiple myeloma and other diseases. Leading pharma companies like Pfizer, Regeneron, and AstraZeneca are advancing treatments includi...

Market News
1 hour ago
Delveinsight
Bullish
news icon
Over 100 BCMA-targeted therapies in development are driving innovation in multiple myeloma treatment.

Existing-home sales fell 5.5% in October, hitting lowest levels since 2010 amid rising mortgage rates.

Existing-home sales in the U.S. dropped 5.5% month-over-month and 8.8% year-over-year in October, reaching the lowest level since August 2010. The decline is attributed to mortgage rates rising to their highest since 2000, making home buying more dif...

Market News
4 hours ago
National Association Of Realtors®
Bearish
news icon
Existing-home sales fell 5.5% in October, hitting lowest levels since 2010 amid rising mortgage rates.

atQor named finalist for 2026 Microsoft Partner of the Year for agentic AI solutions across industries

atQor has been named a finalist for the 2026 Microsoft Partner of the Year Award in the Agents category, recognized for its innovative and scalable agentic AI solutions deployed across nine industries. The company developed 252 AI agents in FY26, wit...

Market News
4 hours ago
Atqor Corporate Communications
Bullish
news icon
atQor named finalist for 2026 Microsoft Partner of the Year for agentic AI solutions across industries
Catch up fast with Aura AI
Get an AI-generated news summary for this asset in seconds.

People also bought

Frequently Asked Questions

US stocks trading hours: Monday - Friday (Except for US public holidays) Time: 21.30 - 04.00 WIB 20.30 - 03.00 WIB (Daylight Savings Time*) *The next Daylight Savings is scheduled to begin on March 13, 2022 and ends on November 6, 2022. You can place limit orders outside of the trading hours, but it can only be executed during trading hours. For illustration, a stock is currently trading at $10 per share, but you only want to pay $7 per share at most. Let’s say you set your limit price to $7 at 18.00. Your order will be executed when the market is open at 21.30 if the stock drops from $10 to $7 or lower. Similarly, if the stock price doesn’t drop to $7, your order won’t be executed.
Yes, you are eligible to receive dividend payment if and when the company pays them on one condition: minimum net dividend paid is at least $0.01. Net dividend is gross dividend subtracted by 15% withholding tax.
Yes, it is. US Stocks risk is managed by PT PG Berjangka which is licensed by Badan Pengawas Perdagangan Berjangka Komoditi (BAPPEBTI), and your investment is guaranteed by Jakarta Futures Exchange (JFX) and Indonesian Clearing House (KBI).
Pluang charges a fixed transaction fee of 0.30% for regular users and 0.20% for Pluang Plus members, including VAT to cover the exchange fees and operational costs.
US Stocks, ETFs, and Options are facilitated by PT PG Berjangka in its capacity as a Licensed Derivatives Broker supervised by the Financial Services Authority of Indonesia (OJK) for financial derivative products with underlying securities. All transactions are recorded on the Jakarta Futures Exchange (JFX) and the Indonesian Futures Clearing House (KBI). In addition, PT PG Berjangka is also a Licensed Futures Broker supervised by the Commodity Futures Trading Regulatory Agency (Bappebti). Read our product’s Terms and Conditions

All investments involve risks and the possibility of a loss in investment value. Past performance is not indicative of future results. Historical performance, expected returns, and probability projections are provided for informational and illustrative purposes only.

Key Stats

  • Market Cap
    $99.25B
  • Volume
    1,220,674
  • Sector
    Health
  • 52W High
    $973.36
  • 52W Low
    $600.66
  • Typical Hold Time
    108 Days
  • Enterprise Value
    $92.65B
  • Div Yield
    0.39%
  • Trading Activity
    0% Sell | 100% Buy
$952.78
52W Low: $600.66
01 Jun 2026
52W High: $973.36
03 Nov 2026

Track Regeneron Pharmaceuticals Inc (REGN) stock price today on Pluang, updated in real time with live charts and market data. Over the past 52 weeks, Regeneron Pharmaceuticals Inc has traded between a low of $600.66 and a high of $973.36, highlighting its annual price range. Buy and sell Regeneron Pharmaceuticals Inc shares on Pluang with fractional shares and real-time market data — safe and OJK-regulated.

Let’s invest in this asset by signing up or download!